Physician profile
Heather Rubinate
NPI 1891191219
$3,359.12
in general payments reported to CMS, 2019-2025
19 companies · $2,415 in 2025
The $2,415 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.33 · 2022: $87.95 · 2023: $297 · 2024: $524 · 2025: $2,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851 · Consulting Fee: $1,360 · Travel and Lodging: $25.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.64 |
| Consulting Fee | $1,360.00 |
| Travel and Lodging | $25.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,860.89 | 2021-2025 | Talvey, Rybrevant, Carvykti |
| Sanofi-Aventis U.S. LLC | $545.88 | 2024-2025 | |
| Amgen INC. | $201.04 | 2022-2025 | Kyprolis, Blincyto, Blincyto |
| Legend Biotech USA INC. | $162.92 | 2024-2025 | Carvykti |
| Astellas Pharma US INC | $128.55 | 2023-2024 | Cresemba, Xospata |
| Novartis Pharmaceuticals Corporation | $97.60 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $67.49 | 2023-2024 | Ultomiris |
| Genzyme Corporation | $38.99 | 2025 | |
| Daiichi Sankyo INC. | $38.95 | 2024 | Injectafer, Vanflyta |
| Morphosys, US INC. | $32.02 | 2022-2023 | Monjuvi |
| Celgene Corporation | $30.10 | 2023 | Onureg |
| Abbvie INC. | $24.59 | 2024 | |
| Karyopharm Therapeutics INC. | $22.94 | 2023 | Xpovio |
| Pharmaessentia USA Corporation | $22.74 | 2023 | Besremi |
| Sobi, INC | $20.37 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $18.42 | 2025 | Darzalex, Talvey, Carvykti |
| Genmab U.S., INC. | $16.40 | 2024 | Tivdak |
| Genentech USA, INC. | $15.49 | 2025 | Polivy |
| Incyte Corporation | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Rubinate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.